SCD patients free of VOEs after treatment with gene-editing therapy
Nearly all the patients with severe sickle cell disease (SCD) who were treated with renizgamglogene autogedtemcel (reni-cel) remained free of vaso-occlusive events (VOEs) for up to two years, new data from the Phase 1/2/3 RUBY clinical trial shows. The treatment also increased total hemoglobin levels and was well tolerated,…